Global Acute Respiratory Distress Syndrome (ARDS) Market Projected to Reach $2.17 Billion by 2029 at a CAGR of 11%
Discover trends, market shifts, and competitive outlooks for the acute respiratory distress syndrome (ards) industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research
What is the Projected CAGR for the Acute Respiratory Distress Syndrome (ARDS) Market Size from 2025 to 2034?
In recent past, the market size of acute respiratory distress syndrome (ARDS) has witnessed a significant boost. The expansion is projected from $1.29 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 10.4%. The extraordinary development during the historic phase is attributable to enhancements in critical care medication, a rising elderly population, the introduction of pulmonary rehabilitation, and the establishment of multidisciplinary care teams.
The market for acute respiratory distress syndrome (ARDS) is projected to experience significant expansion in the coming years. The forecast is set to reach $2.17 billion in 2029, with a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this expected growth include developments in global healthcare readiness, vaccine creation, infectious disease control, telemedical services and remote monitoring, as well as patient-focused care models. Key trends predicted for this timeframe are artificial lung devices, tailored ventilation tactics, lung protective ventilation, and medication therapies for different ards subtypes.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13005&type=smp
What are the Fundamental Drivers and Innovations Shaping the Acute Respiratory Distress Syndrome (ARDS) Market?
The acute respiratory distress syndrome (ARDS) market is anticipated to surge due to the escalating incidence of pneumonia. Pneumonia, a lung infection that fills the air sacs or alveoli in one or both lungs with fluid or pus, triggers an inflammatory response in the lungs. This response increases the permeability of blood vessels and leakage of fluid into the alveoli, obstructing the oxygen-carbon dioxide exchange and leading to respiratory distress. In November 2023, data from the UK’s Centre for Tropical Medicine and Global Health noted a substantial rise in pneumonia cases in Kenya, registering 793,864 cases in 2022-2023 from 477,186 cases in 2020-2021. Therefore, this rise in pneumonia occurrence propels the expansion of the ARDS market.
Acute Respiratory Distress Syndrome (ARDS) Market Driver: The Surge in Respiratory Diseases is Projected to Favor the Growth of the ARDS Market
How Is the Acute Respiratory Distress Syndrome (ARDS) Market Segmented?
The acute respiratory distress syndrome (ARDS) market covered in this report is segmented –
1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests, Lung Function Tests, Other Diagnostic Methods
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care, Other Treatment Options
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=13005&type=smp
Which Regions Are Driving the Next Phase of the Acute Respiratory Distress Syndrome (ARDS) Market Growth?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2024. The regions covered in acute respiratory distress syndrome (ARDS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Key Trends Are Shaping the Future of the Acute Respiratory Distress Syndrome (ARDS) Market?
Leading corporations in the Acute Respiratory Distress Syndrome (ARDS) market are concentrating their efforts on creating innovative therapeutics and supplements like Aviptadil, HSP90 inhibitors, etc., to maintain their market prominence. Aviptadil, a synthesized variant of vasoactive intestinal peptide (VIP), has an affinity for receptors on alveolar type II lung cells. For example, Zuventus Healthcare Ltd., a pharmaceutical manufacturer based in India, introduced Aviptadil to the ARDS treatment market in November 2022. Aviptadil, a supplement of vasoactive intestinal peptide, enhances respiratory function and reduces ARDS fatalities. This is achieved by Aviptadil’s capacity to defend and regenerate Type-2 Pneumocytes, rejuvenate Type-1 Pneumocytes, stimulate surfactant production, and inhibit both IL-6 (interleukin 6) and Tumor Necrosis Factor (TNF)-alpha.
View the full report here:
How Is the Acute Respiratory Distress Syndrome (ARDS) Market Defined and What Are Its Core Parameters?
Acute respiratory distress syndrome (ARDS) is a potentially fatal illness characterized by non-compliant, or stiff lungs and low oxygenation. It is an acute, diffuse and inflammatory form of lung injury that can occur in seriously ill patients. Acute respiratory distress syndrome (ARDS) treatment involves mechanical ventilation with low tidal volumes and positive end-expiratory pressure (PEEP) to support oxygenation and prevent lung injury.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13005
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
